TEL AVIV, Israel
May 10, 2012
/PRNewswire/ -- InspireMD, Inc. (OTC BB: NSPR) (the "Company" or "InspireMD"), a medical device company focusing on the development and commercialization of its proprietary stent platform technology for use in patients with Acute Myocardial Infarctions, will host a symposium and cocktail reception at the EuroPCR meeting on
Wednesday, May 16
Results from the EF (extended follow up) MAGICAL trial will be presented for the first time at this symposium. This is a retrospective analysis of the MAGICAL trial population with follow-up duration of 3 years. MAGICAL was a prospective, single arm study that enrolled 60 STEMI patients with less than 12 hours symptom onset. Primary endpoints were ST segment resolution, TIMI flow and Blush score. The data from the EF MAGICAL trial will be presented by the principal investigator, Dr.
from the Jagiellonian University, Krakow,
The symposium will also feature the first European presentation of the MICAMI trial, which is the first prospective randomized study with MGuard™, that demonstrated a statistically significant improvement in acute outcomes in STEMI patients when compared with traditional bare metal stents (BMS). This data was presented earlier this year in
by principal investigator Dr.
Pontifical Catholic University
"Thrombus Management in STEMI: MGuard ™ Late Breaking Data"
will take place at Concorde Lafayette Hotel (Grande Etoile D'Or Hall) in
Wednesday May 16
, from 6.30 –
EuroPCR is the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions. It serves as one of the leading international courses in Interventional Medicine. It will take place this year in
– 18. More than 12,000 participants from around the world are expected to attend.
MGuard™ combines a coronary stent merged with an embolic protection specifically designed for acute MI patients. The embolic protection is comprised of an ultra-thin polymer micron net that wraps the stent. The MGuard™ stent seeks to provide outstanding and lifelong embolic protection, without affecting deliverability. MGuard™ is CE Mark approved. Mesh-based protection is now recommended for use in the recent Guidelines of the Task force of Myocardial Revascularization of the European Society of Cardiology (ESC).